TrialBone marrow transplantation2026

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

Daniele Avenoso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.